

Illinois Prescription Monitoring Program

Update - May 2023

Subscribe to follow us @ILPMP on YouTube



View as Webpage


FDA Updates Opioid Prescribing Information





As part of its ongoing efforts to address the nation's opioid crisis, the U.S. Food and Drug Administration (FDA) is making several updates to the prescribing information of opioid pain medicines to provide additional guidance on the use of these powerful medicines. Opioid pain medicines are an important treatment option when used as prescribed; however, they also have serious risks, including misuse and abuse, addiction, overdose, and death.

Read More

ILPMP Featured Stats: October 2022 - March 2023







Legislation Update

- **SB 285** has now passed both Senate and House chambers. This bill regarding the **ILPMP** removes an outdated data submission process and removes a data field, "Date Dispensed" as this field is not in the American Society for Automation in Pharmacy's national standard. Provides that it is the responsibility of any new, ceased, or unconnected healthcare facility and its selected Electronic Health Records System or Pharmacy Management System to make contact with and ensure integration with the Prescription Monitoring Program. Provides that subject to specified statutory requirements and limitations and as provided in the administrative rule, the Department of Human Services shall not require, either expressly or effectively, Electronic Health Records Systems, pharmacies, or other providers to utilize a particular entity or system for access to the integration of pharmacy records with the Prescription Monitoring Program.
- **SB 199** has now passed both Senate and House chambers. This bill provides that the scope of practice of an **advanced practice registered nurse with full practice authority** includes prescribing up to a 120-day supply of benzodiazepines without a consultation relationship with a physician. Provides that thereafter, continued prescription of benzodiazepines shall require a consultation with a physician.
- **SB 218** has now passed both Senate and House chambers. Provides that any **physician assistant** required to enter into a written collaborative agreement with a collaborating physician is authorized to continue to practice for up to 90 days after the termination of a written collaborative agreement, provided the physician assistant seeks any necessary collaboration at a local hospital and refers patients who require services beyond the training and experience of the physician assistant to a physician or other health care provider. Provides that physicians and physician assistants who work in a federally qualified health center are exempt from specified collaborative ratio restriction requirements. Adds physician assistants providing services in federally qualified health centers to provisions that authorize certain physician assistants to provide services without a written collaborative agreement and to prescribe certain controlled substances. Defines "federally qualified health center". Makes conforming and other changes.

SIU School of Medicine Releases New Awareness Video on Naloxone

The Importance of Naloxone: A Life-Saving Medicine for Opioid Overdoses

Naloxone is the overdose, nasal spray, or injection we can use to reverse an opioid overdose. And it's a life-saving medicine. The research has shown that having naloxone widely available to



anyone who wants it, whether on an opioid or not, is how we can reduce opioid overdoses as a nation.

SIU Medicine YouTube Channel

New DEA One-Time Training Requirement

The Consolidated Appropriations Act of 2023 enacted a new one-time, eight-hour training requirement for all Drug Enforcement Administration (DEA)-registered practitioners on the treatment and management of patients with opioid or other substance use disorders. This applies to all DEA-registered practitioners, excluding only veterinarians. Beginning June 27, practitioners will be required to check a box on the online registration form at renewal or initial registration, affirming the completion of the new training requirement.



More Information

Educational Resources

VIRTUAL LUNCH AND LEARN SERIES

ILPMP UPDATES & NEW FEATURES

June 22nd 12:00PM CST

PRESENTED BY:
ERIC HUFF, PHARMD, MBA
CLINICAL PROJECT MANAGER



MODERATED BY:

Chris Herndon, PharmD Professor, SIUE

This webinar is not approved for continuing education



NEW Webinar: Continuing Medical Education

Benefits of a Designee



College of Pharmacy

Webinar

- Describe the ILPMP program and registration process
- Explain how a prescriber can assign a designee
- Identify the capabilities and responsibilities of a prescriber and designee within the ILPMP
- Discuss the importance and benefits of assigning designee(s)
- 1.0 contact hour CME

DEA Extends Pandemic Era Policy That Allows Telehealth Docs To Prescribe Controlled Substances

The Drug Enforcement Administration and the Substance Abuse and Mental Health Services Administration issued a **temporary rule**, effective Thursday, May 11, when the public health emergency ended. Both agencies will extend a pandemic-era policy until Nov. 11 that allows telemedicine doctors to prescribe controlled substances such as buprenorphine and Adderall without an in-person medical appointment.

Read More

ILPMP.ORG & PMPnow Monthly Data

WEBSITE DATA

APRIL 2023





+0









185 NEW USERS IN APRIL

TOTAL USERS

TOTAL ILPMP PRESCRIBER USERS

TOTAL ILPMP WEBSITE REQUESTS TOTAL PMPNOW CONNECTIONS

1,555

TOTAL PMPNOW REQUESTS

Contact Information

If you have questions about the information that appears in this update or suggestions for future content, please email **dhs.pmp@illinois.gov**. Visit **www.ilpmp.org** for more information.





The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data on Schedule II-V controlled substances, selected drugs of interest, and other health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality provisions of Illinois Law.

Illinois Prescription Monitoring Program | 401 North Fourth Street, Springfield, IL 62702 www.ilpmp.org

<u>Unsubscribe brittany.queen2@illinois.gov</u>

<u>Update Profile |Constant Contact Data Notice</u>

Sent bydhs.pmp@illinois.govin collaboration with

